Cover Image

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

Show other versions (1)
Saved in:
Bibliographic Details
Main Authors: Salwender, Hans (Author) , Bertsch, Uta (Author) , Benner, Axel (Author) , Raab, Marc-Steffen (Author) , Hillengaß, Jens (Author) , Hose, Dirk (Author) , Huhn, Stefanie (Author) , Hundemer, Michael (Author) , Jauch, Anna (Author) , Seidel-Glätzer, Andrea (Author) , Goldschmidt, Hartmut (Author)
Format: Book/Monograph
Language:English
Published: London BioMed Central 2019
Heidelberg Universitätsbibliothek Heidelberg 2019
Online Access:Resolving-System, kostenfrei, Volltext: https://nbn-resolving.de/urn:nbn:de:bsz:16-heidok-265124
Verlag, kostenfrei, Volltext: http://www.ub.uni-heidelberg.de/archiv/26512
Get full text
Author Notes:Hans Salwender, Uta Bertsch, Katja Weisel, Jan Duerig, Christina Kunz, Axel Benner, Igor W. Blau, Marc Steffen Raab, Jens Hillengass, Dirk Hose, Stefanie Huhn, Michael Hundemer, Mindaugas Andrulis, Anna Jauch, Andrea Seidel-Glaetzer, Hans-Walter Lindemann, Manfred Hensel, Stefan Fronhoffs, Uwe Martens, Timon Hansen, Mohammed Wattad, Ullrich Graeven, Markus Munder, Roland Fenk, Mathias Haenel, Christof Scheid and Hartmut Goldschmidt
Description
Item Description:In: BMC Cancer, 19 (2019), Nr. 504. pp. 1-11. ISSN 1471-2407
Physical Description:Online Resource

Similar Items